tbuckley/cabot-search huggingface dataset:
Correlation of pretreatment surgical staging and PET SUVmax with outcomes in NSCLC.
Authors: Giancarlo Moscol, Doraid Jarrar, Huyen Tran, William J. Tester
Journal: Journal of Clinical Oncology (2012)

7051 Background: The AJCC staging does not recognize the number of involved mediastinal lymph nodes (LN), nodal stations or PET findings as prognostic factors in non-small cell lung cancer (NSCLC). Most clinical studies report poorer survival with greater number of involved LN and maximal tumor standardized uptake value (SUVmax) &gt; 5. We hypothesized that clinical outcomes can be predicted by (1) number of involved LN, (2) number of involved nodal stations, (3) SUVmax of primary tumor and (4) SUVmax of mediastinum. Methods: Records of patients diagnosed with NSCLC stages I-IIIA from 1/1/99 to 12/31/10 were reviewed. Data collected included age, type of surgery, AJCC stage, number of LN/stations sampled and SUVmax of primary tumor/mediastinum. Primary outcomes were tumor recurrence and death. Descriptive statistics were used to summarize demographics. Prognostic factors were analyzed by a multivariate analysis using Cox’s proportional hazard model. Survival was estimated by the Kaplan-Meier method. Results: There were 369 patients with complete clinical data; 207 underwent surgical staging with mediastinoscopy (62) or VATS/open thoracotomy (145). The median number of LN sampled was 9 (range 1-35) and the median number of stations biopsied was 3 (range 1-9). PET was performed in 89 patients; 59 scans showed tumor SUVmax &gt; 5. A total of 65/207 patients received chemotherapy. With median follow-up time of 29 months (range 1-116), 73 recurrences and 90 deaths were observed. Cox analysis showed greater recurrence risk for patients with 4 or more involved LN (HR= 4.66, CI=1.19-18.18, p=0.027) and higher mortality for patients with tumor SUVmax &gt; 5 (HR=14.83, CI=2.32-94.9, p=0.004). Outcomes did not correlate with the number of involved nodal stations (p=0.76 for recurrence, p=0.51 for mortality) or with SUVmax of mediastinum (p=0.17 for recurrence, p=0.93 for mortality). Conclusions: The number of involved LN was an independent prognostic factor for recurrence but not for mortality. A tumor SUVmax &gt;5 was independently associated with greater mortality. The number of involved stations and the SUVmax of mediastinum did not correlate with worse outcomes. Our results are limited due to the small number of cases with PET/CT scans and short follow-up.
Diseases of the Nose, Throat and Ear.
Journal: Annals of Internal Medicine (1978)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Preemptive versus reactive topical clobetasol for regorafenib-induced hand-foot reactions: Results from the ReDOS trial.
Authors: Aminah Jatoi, Fang-Shu Ou, Daniel H. Ahn, Patrick McKay Boland, Kristen Keon Ciombor, Nisha Lassi Jacobs, Boris Pasche, James M. Cleary, Jeannine S. McCune, Katrina Pedersen, Afsaneh Barzi, E. Gabriela Chiorean, Erica N. Heying, Heinz-Josef Lenz, Jeff A. Sloan, Mario E. Lacouture, Axel Grothey, Tanios S. Bekaii-Saab
Journal: Journal of Clinical Oncology (2019)

11586 Background: Hand-foot skin reaction (HFSR) is the most common regorafenib adverse event. However, no intervention has demonstrated efficacy in preventing or palliating this adverse event, short of modulating the regorafenib dose. Methods: The Regorafenib Dose Optimization Study (ReDOS) was a randomized trial ( https://clinicaltrials.gov/ct2/show/NCT02368886 ); here we describe an a priori secondary analysis of ReDOS with the goal of assessing whether clobetasol 0.05% cream (a potent corticosteroid) applied to the palms and soles twice per day is more effective when prescribed pre-emptively (before the development of HFSR) versus reactively (after the development of HFSR). Patients were assessed during the 1 st 2 cycles of regorafenib. Results: Among 116 evaluable patients, 61 received pre-emptive clobetasol, and 55 reactive clobetasol. Baseline demographics were comparable between groups. During the 1st regorafenib cycle, 46% and 52% of patients developed HFSR with pre-emptive and reactive clobetasol, respectively (p = 0.52). However, during the 2nd cycle, 56% (of 47 total patients) and 80% (of 41 total patients), developed this toxicity with pre-emptive and reactive clobetasol, respectively (p = 0.02). Of note, during the 2nd cycle, rates of grade 1,2, and 3 HFSR were 40%, 11%, and 4% (pre-emptive) and 45%, 25%, and 10% (reactive) (p = 0.07). A sensitivity analysis to examine rates of no HFSR over all 2 regorafenib cycles showed that no HFSR occurred in 33% (of 61 total patients) with pre-emptive clobetasol versus 15% (of 55 total patients) with reactive clobetasol (p = 0.02). Patient-reported outcomes showed HFSR compromised activities of daily living, including getting dressed, preparing meals, walking, and even driving, with seemingly worse descriptive outcomes in patients who received reactive therapy. No adverse events from clobetasol were reported. Conclusions: Compared to reactive therapy, pre-emptive topical clobetasol might lessen regorafenib-induced HFSR. Clinical trial information: NCT02368886.
Few training sessions between return to play and first match appearance are associated with an increased propensity for injury: a prospective cohort study of male professional football players during 16 consecutive seasons
Authors: Håkan Bengtsson, Jan Ekstrand, Markus Waldén, Martin Hägglund
Journal: British Journal of Sports Medicine (2019)

It has been hypothesised that injury risk after return to play following an injury absence is influenced by the amount of training completed before return to competition.To analyse if the number of completed training sessions between return to play and the first subsequent match appearance was associated with the odds of injury in men's professional football.From a cohort study, including 303 637 individual matches, 4805 first match appearances after return to play following moderate to severe injuries (≥8 days absence) were analysed. Rate ratios (RRs) were used to compare injury rates in the first match appearances with the average seasonal match injury rate. Odds ratios (ORs) were used to analyse associations between the number of completed training sessions and general (all injuries), muscle, and non-muscle injury odds.Injury rate in the first match after return to play was increased by 87% compared with the average seasonal match injury rate (46.9 vs 25.0/1000 hours, RR=1.87; 95% CI 1.64 to 2.14). The odds of injury dropped 7% with each training session before the first match (OR 0.93; 95% CI 0.87 to 0.98). The same association was found for muscle injuries (OR 0.87; 95% CI 0.79 to 0.95) but not for non-muscle injuries (OR 0.99; 95% CI 0.91 to 1.07).Injury rates in the first match after injury are higher than the average seasonal match injury rate, but the propensity for player injury is decreased when players complete more training sessions before their first match.
Non-Hodgkin's lymphoma (NHL) patients at a VA medical center: Comorbidity and treatment
Authors: S. Srinivas, M. Cholankeril, V. T. Chang, E. Morales-Muyuela, L. Duque, K. Toomey, B. Kasimis
Journal: Journal of Clinical Oncology (2009)

e19559 Background: We hypothesized that measures of comorbidity may help explain the number of treatments administered to patients with non-Hodgkin's lymphoma. Methods: We performed a retrospective, IRB approved protocol, using chart review of all patients diagnosed with non-Hodgkin's lymphoma at the VANJHCS from January 1, 1997 through December 31, 2008. Records were reviewed for demographic, clinical, pathological data, the number of chemotherapy regimens, radiation therapy, and total number of treatments and survival. We tabulated the Charlson Comorbidity Index (CMI), the Kaplan-Feinstein Comorbidity Index (KFI), the Cumulative Illness Rating Scale (CIRS), International Prognostic Index (IPI), and performance status (PS) were tabulated for 100 patients seen at a VA Medical Center. Results: There were 100 patients with median (M) age 62 years (27–89). There were 61 deaths (61%) with M survival(MS) 1068 days(13–3976). The M Stage was 1(0–4), M LDH was 204 IU/L (88–1905), M Hgb 12.3gm/dL (7.3–17.4), M Albumin was 3.8g/dl(1.2–5.4), M Zubrod Performance Status(PS) was 1(0–4) in 50 pts(50%). The M CMI was 6(1–12), M KFI was 3(1–3), M CIRS17 was 1.7(1–3.15). The M total number of systemic therapy regimens received was 1(0–4.5), M radiotherapy was 0(0–1) and the overall M total treatment regimens used was 1 (0–4.5). IPI was a significant predictor in the use of radiation therapy (p&lt;0.054) but did not correlate with the use systemic therapy. The CMI was a predictor of the use of systemic chemotherapy (p&lt;0.007), and the total number of treatments received (p&lt;0.011), but not the KFI or the CIRS 17. The performance status did not predict for the number of treatments. In a Cox regression analysis, the number of treatments did not affect survival. Conclusions: This data provides evidence that one measure of comorbidity, the CMI, may partially explain the number of systemic therapy treatments, and total treatments received by NHL patients. Further work in larger groups of pts is warranted. No significant financial relationships to disclose.
HIV-Nef Protein Transfer to Endothelial Cells Requires Rac1 Activation and Leads to Endothelial Dysfunction Implications for Statin Treatment in HIV Patients
Authors: Sarvesh Chelvanambi, Samir K. Gupta, Xingjuan Chen, Bradley W. Ellis, Bernhard F. Maier, Tyler M. Colbert, Jithin Kuriakose, Pinar Zorlutuna, Paul Jolicoeur, Alexander G. Obukhov, Matthias Clauss
Journal: Circulation Research (2019)

Rationale: Even in antiretroviral therapy-treated patients, HIV continues to play a pathogenic role in cardiovascular diseases. A possible cofactor may be persistence of the early HIV response gene Nef, which we have demonstrated recently to persist in the lungs of HIV+ patients on antiretroviral therapy. Previously, we have reported that HIV strains with Nef, but not Nef-deleted HIV strains, cause endothelial proinflammatory activation and apoptosis. Objective: To characterize mechanisms through which HIV-Nef leads to the development of cardiovascular diseases using ex vivo tissue culture approaches as well as interventional experiments in transgenic murine models. Methods and Results: Extracellular vesicles derived from both peripheral blood mononuclear cells and plasma from HIV+ patient blood samples induced human coronary artery endothelial cells dysfunction. Plasma-derived extracellular vesicles from antiretroviral therapy+ patients who were HIV-Nef+ induced significantly greater endothelial apoptosis compared with HIV-Nef-plasma extracellular vesicles. Both HIV-Nef expressing T cells and HIV-Nef-induced extracellular vesicles increased transfer of cytosol and Nef protein to endothelial monolayers in a Rac1-dependent manner, consequently leading to endothelial adhesion protein upregulation and apoptosis. HIV-Nef induced Rac1 activation also led to dsDNA breaks in endothelial colony forming cells, thereby resulting in endothelial colony forming cell premature senescence and endothelial nitric oxide synthase downregulation. These Rac1-dependent activities were characterized by NOX2-mediated reactive oxygen species production. Statin treatment equally inhibited Rac1 inhibition in preventing or reversing all HIV-Nef-induction abnormalities assessed. This was likely because of the ability of statins to block Rac1 prenylation as geranylgeranyl transferase inhibitors were effective in inhibiting HIV-Nef-induced reactive oxygen species formation. Finally, transgenic expression of HIV-Nef in endothelial cells in a murine model impaired endothelium-mediated aortic ring dilation, which was then reversed by 3-week treatment with 5 mg/kg atorvastatin. Conclusions: These studies establish a mechanism by which HIV-Nef persistence despite antiretroviral therapy could contribute to ongoing HIV-related vascular dysfunction, which may then be ameliorated by statin treatment.
The Modern Mastoid Operation.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Saving lives and costs through screening (Sc) for colorectal cancer (CRC): Implications for limited-resource healthcare systems (LRHS).
Authors: Afsaneh Barzi, Michael Directo, Sriram Dasu, Heinz-Josef Lenz, Sarmad Sadeghi
Journal: Journal of Clinical Oncology (2013)

6545 Background: While USPSTF and ACP have determined that Sc for CRC is beneficial, the practice of Sc and its benefits are not established in LRHS caring for the uninsured. We tested the hypothesis that Sc could result in a reduction in the therapy (Tx) costs for CRC and offset Sc costs. Methods: Using a Markov model we performed individual level microsimulations (ILMS) of 100,000 subjects ≥ 50 years with average risk of CRC. Five Sc strategies (ST) were tested: Fecal occult blood (FOBT) and fecal immune chemical (FIT) annually and biannually (FOBT2, FIT2), and colonoscopy (CS) every 10 years. No Sc was used as referent ST (Ref). Compliance with Sc was assumed at 16% for FOBT and FIT and 56% for CS. Sc was offered to 100, 50 and 25% of the subjects in 3 separate ILMS. Life Years Gained (LYG) and Incremental Cost Effectiveness Ratios (ICER) were calculated. Costs and LYG discounted at 3%. Results: Mean follow up: 12.6 years. At all coverage levels all STs resulted in decreased CRC costs by 9-17% and deaths by 14-41%. CS decreases CRC incidence by 5-26%. At higher coverage rates, CS remains the best ST, but at 25% and lower coverage FOBT and FIT function better. Conclusions: These data support systematic use of Sc for CRC in LRHS. Until resources for CS are available, lives and costs could be saved by simple measures such as FOBT and FIT and enrolling as few as 4,552 subjects. [Table: see text]
miRNA Profiling in Pediatric T-ALL with Use of Next-Generation Sequencing: Focus on T-ALL Pathobiology and Heterogeneity
Authors: Małgorzata Dawidowska, Bronisława Szarzyńska-Zawadzka, Roman Jaksik, Monika Drobna, Maria Kosmalska, Sędek Łukasz, Tomasz Szczepański, Michał Witt
Journal: Blood (2017)
Assessing the health effects of a “no deal” Brexit
Authors: May C I van Schalkwyk, Pepita Barlow, David Stuckler, Maggie Rae, Tim Lang, Tamara Hervey, Martin McKee
Journal: BMJ (2019)

Any form of Brexit is a threat to health and the NHS but leaving without a deal is a leap in the dark Key Messages:1. Leaving the EU without a deal threatens health and the NHS in many ways, but the scale of the threat remains unclear. A No DealBrexit is likely to have severe and profound consequences for health and the NHS and we propose a framework that could be the basis for the comprehensive health impact assessment that is needed to inform politicians and the public.3. The time and money being used to prepare for No Deal could be much better used to support sectors that are already struggling.4. The government's claims that it is prepared for No Deal are implausible and, at best, might mitigate some of the worst consequences.
Prognostic significance of tumor stromal and epithelial claudin 2 in metastatic colorectal cancer.
Authors: Artur Mezheyeuski, Tormod Kyrre Guren, Bengt Glimelius, Per Pfeiffer, Elin Kure, Tone Ikdahl, Eva Skovlund, Halfdan Sorbye, Kjell Magne Tveit, Kristian Pietras, Per Sandstrom, Linda Bojmar, Anna Portyanko, Arne Ostman
Journal: Journal of Clinical Oncology (2013)

3597 Background: Tight junctions (TJ) are the most apical epithelial cell–cell adhesions. Claudin super-family trans-membrane proteins, including claudin 2 (cl2), are important components of TJs. Expression of cl2 has been reported to be elevated in colorectal cancer (CRC) and its up-regulation increases tumorigenicity of CRC cells in vitro. The aim of this study was to analyze the prognostic significance of cl2 in CRC. Methods: A tissue microarray (TMA) from the stage IV CRC patients of the phase III NORDIC-VII study was used. Cl2 IHC staining was evaluated in a semi-quantitative manner in cancer cells (cl2-C) and in the tumor stroma (cl2-S). Primary fibroblasts were established from human CRC tumor tissue and non-tumor colon tissue, and evaluated by immunoblotting. Results: Analyses of the TMA derived from the NORDIC-VII cohort revealed that cancer cell expression and tumor stroma expression of cl2 was associated with shorter OS in a Log-Rank test for trend (cl2-C, n=315, p=0.018; cl2-S, n=319, p=0.020). Expression of cl2-S, but not cl2-C was prognostic in multivariate analysis including WHO performance status, alkaline phosphatase level and BRAF mutation status (HR=1.30; 95% CI 1.08-1.56; p=0.006). When cl2-C and cl2-S expression was combined the prognostic significance was increased. The group with high cl2-C and high cl2-S (N=182), when compared with the rest of the cases (n=129), displayed a worse prognosis in terms of OS (19.1 mo vs 27.2 mo; p=0.003) in univariate analyses (HR=1.55, 95% CI 1.16-2.08, p=0.003) and in multivariate analyses (HR=1.52, 95% CI 1.13-2.05, p=0.006). Immunoblotting analysis of primary cultures of fibroblasts confirmed cl2 expression in fibroblasts from CRC tissue and from non-tumor tissue, with higher expression observed in the tumor fibroblasts. Conclusions: CRC display a previously un-reported stromal expression of cl2 of prognostic significance. High cl2-S is associated with worse prognosis in patients with metastatic CRC, in a manner independent of WHO status, alkaline phosphatase levels and BRAF status. Furthermore, high expression of cl2 in both cancer cells and the tumor stroma is also associated with poor prognosis.
Using Birth Cohort Data to Estimate Prenatal Chemical Exposures for All Births around the New Bedford Harbor Superfund Site in Massachusetts
Authors: Roxana Khalili, Scott M. Bartell, Jonathan I. Levy, M. Patricia Fabian, Susan Korrick, Verónica M. Vieira
Journal: Environmental Health Perspectives (2019)

Background: Children born near New Bedford, Massachusetts, have been prenatally exposed to multiple environmental chemicals, in part due to an older housing stock, maternal diet, and proximity to the New Bedford Harbor (NBH) Superfund site. Chemical exposure measures are not available for all births, limiting epidemiologic investigations and potential interventions. Objective: We linked biomonitoring data from the New Bedford Cohort (NBC) and birth record data to predict prenatal exposures for all contemporaneous area births. Methods: We used prenatal exposure biomarker data from the NBC, a population-based cohort of 788 mother–infant pairs born during 1993–1998 to mothers living near the NBH, linked to their corresponding Massachusetts birth record data, to build predictive models for cord serum polychlorinated biphenyls (expressed as a sum, ΣPCBs), p,p′-dichlorodiphenyl dichloroethylene (DDE), hexachlorobenzene (HCB), cord blood lead (Pb), and maternal hair mercury (Hg). We applied the best fit models (highest pseudo R2), with multivariable smooths of continuous variables, to predict exposure biomarkers for all 10,270 births during 1993–1998 around the NBH. We used 10-fold cross validation to validate the exposure models and the bootstrap method to characterize sampling variability in the exposure predictions. Results: The 10-fold cross-validated R2 for the ΣPCBs, DDE, HCB, Pb, and Hg exposure models were 0.54, 0.40, 0.34, 0.46, and 0.40, respectively. For each exposure model, multivariable smooths of continuous variables improved the fit compared with linear models. Other variables with significant effects on exposure estimates were paternal education, maternal race/ethnicity, and maternal ancestry. The resulting exposure predictions for all births had variability consistent with the NBC measured exposures. Conclusions: Predictive models using multivariable smoothing explained reasonable amounts of variance in prenatal exposure biomarkers. Our analyses suggest that prenatal chemical exposures can be predicted for all contemporaneous births in the same geographic area by modeling available biomarker data for a subset of that population. https://doi.org/10.1289/EHP4849
Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)
Authors: Konstantinos C Koskinas, Stephan Windecker, Giovanni Pedrazzini, Christian Mueller, Stéphane Cook, Christian M Matter, Olivier Muller, Jonas Häner, Baris Gencer, Carmela Crljenica, Poorya Amini, Olga Deckarm, Juan F Iglesias, Lorenz Räber, Dik Heg, François Mach
Journal: Journal of the American College of Cardiology (2019)